Indications › Obesity & overweight › retatrutide
retatrutide in obesity & overweight
retatrutide is not approved in the US for obesity & overweight, and has 11 trials on file here in this condition. 8 of them are phase 3 or later. The next scheduled result is 2027-03-14. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.
11 registered trials study retatrutide in obesity & overweight, 5 of them still active and 4 in phase 3. The next is due to report 2027-03-14.
- Trials on file
- 11
- Active
- 5
- Active phase 3
- 4
- Participants in active trials
- 2,379
- Sponsors
- 2
- Scheduled readouts
- 5
Scheduled to report
Dates are filed by the sponsor and move often. Each links to its own record and change history.
| Est. completion | Trial | Phase | Participants |
|---|---|---|---|
| 2027-03-14 | Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight NCT07467447 · Hudson Biotech | P2 | 300 |
| 2027-07 | A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight NCT07232719 · Eli Lilly and Company | P3 | 250 |
| 2027-09 | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain NCT07035093 · Eli Lilly and Company | P3 | 586 |
| 2028-04 | A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity NCT06859268 · Eli Lilly and Company | P3 | 643 |
| 2028-10 | A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight NCT07357415 · Eli Lilly and Company | P3 | 600 |
All trials on file
Every registered trial of retatrutide grouped under obesity & overweight, largest first. Grouping follows the registry’s own condition wording.
See the full record for retatrutide, or every molecule being studied in obesity & overweight. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.